Skip to contentManning Paul B — Verrica Pharmaceuticals Inc. insider: 174 transactions · InsiderLensManning Paul B
- EVP & General Manager, PBM at PERRIGO CO · on record since Jun 22, 2010
- Director at Candel Therapeutics, Inc. · on record since Apr 2, 2026
- Director at Liquidia Corp · on record since Jun 8, 2026
- Director at AveXis, Inc. · on record since Feb 12, 2016
- 10% owner at AveXis, Inc. · on record since Feb 12, 2016
- Director at Dova Pharmaceuticals, Inc. · on record since Jun 28, 2017
- 10% owner at Dova Pharmaceuticals, Inc. · on record since Jun 28, 2017
- Director at Verrica Pharmaceuticals Inc. · on record since Jun 19, 2018
- 10% owner at Verrica Pharmaceuticals Inc. · on record since Jun 19, 2018
- Director at Taysha Gene Therapies, Inc. · on record since Sep 30, 2020
- 10% owner at Taysha Gene Therapies, Inc. · on record since Sep 30, 2020
- 10% owner at Liquidia Corp · on record since Nov 19, 2020
- 10% owner at ARBIOS SYSTEMS INC · on record since Jun 30, 2021
- 10% owner at Candel Therapeutics, Inc. · on record since Aug 4, 2021
- 10% owner at Pasithea Therapeutics Corp. · on record since Feb 14, 2023
Insider trading activity of Manning Paul B
- Transactions on record
- 174
- since Feb 12, 2016
- Open-market buys
- 78
- $110.1M
- Open-market sells
- 10
- $41.7M
- Companies traded
- 7
- last filing Jul 1, 2026
Figures computed from official regulatory filings — methodology.
Companies where Manning Paul B has traded
- Candel Therapeutics, Inc.22 tx · $28.9M · Jul 1, 2026
- Liquidia Corp24 tx · $43.9M · Jun 18, 2026
- Verrica Pharmaceuticals Inc.54 tx · $38M · Nov 25, 2025
- Taysha Gene Therapies, Inc.23 tx · $25.1M · Jun 3, 2025
- ARBIOS SYSTEMS INC6 tx · $5M · Jul 8, 2021
- Dova Pharmaceuticals, Inc.21 tx · $416.4M · Nov 12, 2019
- AveXis, Inc.24 tx · $10M · May 15, 2018
Track record of Manning Paul B
Statistical track record
Free- Open-market buys
- 84
- Last buy
- Feb 23, 2026
Win rates and median returns are available with a free account (5 insiders/month).
Create a free account→Transaction history of Manning Paul B
Co-insiders of Manning Paul B
This page republishes public regulatory disclosures. Concerned by this data? Exercise your right to object →
Nguyen DiemCandel Therapeutics, Inc. +1
| Company | Filed | Type | Qty | Price | Value · USD | Src |
|---|
| Jul 1, 2026 | AwardD | 2,199 | 8.64 USD | — | SEC |
| Jun 24, 2026 | AwardD | 32,000 | 0.00 USD | — | SEC |
| Jun 18, 2026 | Award | 5,882 | 0.00 USD | — | SEC |
| Jun 8, 2026 | Sell | -68,265 | 63.83 USD | $4.4M | SEC |
| Jun 8, 2026 | Sell | -11,513 | 63.13 USD | $726.8K | SEC |
| Jun 8, 2026 | Sell | -12,610 | 64.42 USD | $812.3K | SEC |
| Jun 8, 2026 | Sell | -88,487 | 64.28 USD | $5.7M | SEC |
| Jun 8, 2026 | Sell | -19,125 | 62.62 USD | $1.2M | SEC |
| Apr 2, 2026 | AwardD | 4,618 | 4.11 USD | $19K | SEC |
| Feb 26, 2026 | Buy | 550,458 | 5.45 USD | $3M | SEC |
| Feb 12, 2026 | Other | -55,116 | 42.63 USD | $2.3M | SEC |
| Feb 12, 2026 | Other | 55,116 | 42.63 USD | $2.3M | SEC |
| Nov 25, 2025 | Buy | 2,750,762 | 4.24 USD | $11.7M | SEC |
| Nov 25, 2025 | BuyD | 687,690 | — | — | SEC |
| Nov 25, 2025 | Buy | 1,375,380 | 4.24 USD | $5.8M | SEC |
| Nov 25, 2025 | BuyD | 343,845 | — | — | SEC |
| Sep 2, 2025 | Sell | -74,230 | 29.14 USD | $2.2M | SEC |
| Sep 2, 2025 | Sell | -154,337 | 27.94 USD | $4.3M | SEC |
| Sep 2, 2025 | Sell | -254,038 | 28.67 USD | $7.3M | SEC |
| Sep 2, 2025 | Sell | -188,232 | 27.62 USD | $5.2M | SEC |
| Jun 26, 2025 | Award | 1,070,663 | 4.67 USD | $5M | SEC |
| Jun 20, 2025 | Award | 18,396 | 0.00 USD | $0 | SEC |
| Jun 18, 2025 | AwardD | 14,240 | 0.00 USD | $0 | SEC |
| Jun 3, 2025 | Buy | 750,000 | 2.75 USD | $2.1M | SEC |
| Dec 18, 2024 | Buy | 500,000 | 6.00 USD | $3M | SEC |